Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
Acta Obstet Gynecol Scand. 2021 Apr;100(4):684-693. doi: 10.1111/aogs.13919. Epub 2020 Jun 2.
The use of oxytocin to augment labor is increasing in many low-resource settings; however, little is known about the effects of such use in contexts where resources for intrapartum monitoring are scarce. In this study, we sought to assess the association between augmentation of labor with oxytocin and delivery outcomes.
We conducted a cohort study in 12 public hospitals in Nepal, including all deliveries with and without augmentation of labor with oxytocin, but excluding elective cesarean sections, women with missing information on augmentation of labor, and women without fetal heart rate on admission. Bivariate and multivariate logistic regression calculating the crude and adjusted risk ratio (aRR) with corresponding 95% CI were performed, comparing (a) intrapartum stillbirth and first-day mortality (primary outcome); and (b) intrapartum monitoring, mode of delivery, postpartum hemorrhage, bag-and-mask ventilation of the newborn, Apgar score, and neonatal death before discharge (secondary outcomes) among women with and without oxytocin-augmented labor.
The total cohort consisted of 78 931 women, of whom 28 915 (37%) had labor augmented with oxytocin and 50 016 (63%) did not have labor augmented with oxytocin. Women with augmentation of labor had no increased risk of intrapartum stillbirth and first-day mortality (aRR 1.24, 95% CI 0.65-2.4), but decreased risks of suboptimal partograph use (aRR 0.71, 95% CI 0.68-0.74), suboptimal fetal heart rate monitoring (aRR 0.50, 95% CI 0.48-0.53), and emergency cesarean section (aRR 0.62, 95% CI 0.59-0.66), and increased risks of bag-and-mask ventilation (aRR 2.1, 95% CI 1.8-2.5), Apgar score <7 at 5 minutes (aRR 1.65, 95% CI 1.49-1.86), and neonatal death (aRR 1.93, 95% CI 1.46-2.56).
Although augmentation of labor with oxytocin might be associated with beneficial effects, such as improved monitoring and a decreased risk of cesarean section, its use may lead to an increased risk of adverse perinatal outcomes. We urge for a cautious use of oxytocin to augment labor in low-resource contexts, and call for evidence-based guidelines on augmentation of labor in low-resource settings.
在许多资源匮乏的环境中,催产素用于引产的情况越来越多;然而,对于资源匮乏的产程中监测的情况下,这种使用的效果知之甚少。在这项研究中,我们旨在评估用催产素引产与分娩结局之间的关联。
我们在尼泊尔的 12 家公立医院进行了一项队列研究,包括所有用和不用催产素引产的分娩,但不包括选择性剖宫产、缺乏引产信息的妇女以及入院时没有胎心的妇女。我们进行了单变量和多变量逻辑回归分析,计算了粗风险比(crude risk ratio,cRR)和调整风险比(adjusted risk ratio,aRR),并比较了(a)产程中死产和第 1 天死亡率(主要结局);以及(b)产程中监测、分娩方式、产后出血、新生儿气囊面罩通气、新生儿 Apgar 评分和新生儿出院前死亡(次要结局)在使用和不使用催产素引产的妇女中的差异。
总队列包括 78931 名妇女,其中 28915 名(37%)用催产素引产,50016 名(63%)未用催产素引产。用催产素引产的妇女产程中死产和第 1 天死亡率没有增加的风险(aRR 1.24,95%CI 0.65-2.4),但部分产程图使用不佳(aRR 0.71,95%CI 0.68-0.74)、胎心监测不佳(aRR 0.50,95%CI 0.48-0.53)和紧急剖宫产(aRR 0.62,95%CI 0.59-0.66)的风险降低,气囊面罩通气(aRR 2.1,95%CI 1.8-2.5)、新生儿 Apgar 评分<7 分(aRR 1.65,95%CI 1.49-1.86)和新生儿死亡(aRR 1.93,95%CI 1.46-2.56)的风险增加。
虽然用催产素引产可能会有有益的效果,如改善监测和降低剖宫产率,但它的使用可能会导致围产期不良结局的风险增加。我们敦促在资源匮乏的情况下谨慎使用催产素引产,并呼吁制定基于证据的资源匮乏环境下的催产素引产指南。